Relative effectiveness of sunitinib versus everolimus in advanced pancreatic neuroendocrine tumors: an updated matching-adjusted indirect comparison

被引：5
|
作者：
Ishak, K. Jack [1 ]
Rael, Michael [2 ]
Hicks, Meagen [3 ]
Mittal, Sangeeta [3 ]
Eatock, Martin [4 ]
Valle, Juan W. [5 ,6 ]
机构：
[1] Evidera Inc, Montreal, PQ, Canada
[2] Evidera Inc, San Francisco, CA 94111 USA
[3] Pfizer Ltd, Walton Oaks, Surrey, England
[4] Belfast City Hosp, Northern Ireland Canc Ctr, Belfast, Antrim, North Ireland
[5] Univ Manchester, Inst Canc Sci, Manchester, Lancs, England
[6] Christie NHS Fdn Trust, Manchester, Lancs, England
来源：
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH | 2018年 / 7卷 / 10期
关键词：
comparative effectiveness; everolimus; MAIC; matching-adjusted indirect comparison; sunitinib;
D O I：
10.2217/cer-2018-0020
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
Aim: A matching-adjusted indirect comparison (MAIC) of sunitinib and everolimus has been previously reported based on the RADIANT-3 everolimus trial. We performed an analysis using updated overall survival (OS) data based on sunitinib's trial (A6181111). Methods: The MAIC matched on all baseline characteristics available from both studies. An anchored MAIC was performed for progression-free survival (PFS); an unanchored analysis was deemed more appropriate for OS due to crossover in both trials. A hazard ratio for sunitinib versus everolimus was derived from adjusted (weighted) sunitinib effects compared with the observed results for everolimus. Results: The adjusted hazard ratio for sunitinib versus everolimus was 0.85 (0.39-1.89) for PFS and 0.82 (0.53-1.27) for OS. Conclusion: Findings indicate comparable PFS and OS with sunitinib and everolimus.
引用
收藏
页码：947 / 958
页数：12
相关论文
共 50 条
  • [21] SECUKINUMAB FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS: COMPARATIVE EFFECTIVENESS RESULTS VERSUS ADALIMUMAB USING A MATCHING-ADJUSTED INDIRECT COMPARISON
    Maksymowych, W.
    Strand, V.
    Baeten, D.
    Nash, P.
    Thom, H.
    Cure, S.
    Palaka, E.
    Gandhi, K.
    Richards, H.
    Jugl, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 98 - 98
  • [22] Comparative effectiveness of secukinumab and adalimumab in ankylosing spondylitis as assessed by matching-adjusted indirect comparison
    Maksymowych, Walter P.
    Strand, Vibeke
    Nash, Peter
    Yazici, Yusuf
    Thom, Howard
    Hunger, Matthias
    Kalyvas, Chrysostomos
    Gandhi, Kunal K.
    Porter, Brian
    Jugl, Steffen M.
    EUROPEAN JOURNAL OF RHEUMATOLOGY, 2018, 5 (04) : 216 - +
  • [23] Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analyses
    Irina Proskorovsky
    Agnes Benedict
    Sylvie Negrier
    Danielle Bargo
    Rickard Sandin
    Krishnan Ramaswamy
    Jigar Desai
    Joseph C. Cappelleri
    James Larkin
    BMC Cancer, 18
  • [24] Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analyses
    Proskorovsky, Irina
    Benedict, Agnes
    Negrier, Sylvie
    Bargo, Danielle
    Sandin, Rickard
    Ramaswamy, Krishnan
    Desai, Jigar
    Cappelleri, Joseph C.
    Larkin, James
    BMC CANCER, 2018, 18
  • [25] Matching-adjusted indirect treatment comparison of ozanimod versus teriflunomide for relapsing multiple sclerosis
    Cohan, Stanley
    Tencer, Tom
    Arndorfer, Stella
    Zhu, Xuelian
    Zivkovic, Marko
    Kumar, Jinender
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 52
  • [26] Matching-adjusted indirect comparison for treatment of NTRK fusion cancer with larotrectinib versus entrectinib
    Garcia-Foncillas, J.
    Bokemeyer, C.
    Italiano, A.
    Keating, K.
    Paracha, N.
    Fellous, M.
    Marian, M.
    Fillbrunn, M.
    Gao, W.
    Ayyagari, R.
    Lassen, U. N.
    ANNALS OF ONCOLOGY, 2021, 32 : S401 - S401
  • [27] Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison
    Nash, Peter
    McInnes, Iain B.
    Mease, Philip J.
    Thom, Howard
    Hunger, Matthias
    Karabis, Andreas
    Gandhi, Kunal
    Mpofu, Shephard
    Jugl, Steffen M.
    RHEUMATOLOGY AND THERAPY, 2018, 5 (01) : 99 - 122
  • [28] Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison
    Peter Nash
    Iain B. McInnes
    Philip J. Mease
    Howard Thom
    Matthias Hunger
    Andreas Karabis
    Kunal Gandhi
    Shephard Mpofu
    Steffen M. Jugl
    Rheumatology and Therapy, 2018, 5 : 99 - 122
  • [29] MATCHING-ADJUSTED INDIRECT COMPARISON: PROLGOLIMAB VERSUS OTHER IMMUNE THERAPIES FOR ADULT PATIENTS WITH ADVANCED MELANOMA IN THE RUSSIAN FEDERATION
    Mladov, V
    Tolkacheva, D.
    Sokolova, V
    VALUE IN HEALTH, 2020, 23 : S528 - S528
  • [30] Anchored matching-adjusted indirect comparison (MAIC) of regorafenib (REG) versus cabozantinib (CAB) in advanced hepatocellular carcinoma (HCC).
    Proskorovsky, Irina
    Krotneva, Mira
    Ozgurdal, Kirhan
    Jaeger, Savina
    Su, Yun
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345